Lippincott Williams & Wilkins
Supplementary Tables
Table 1. Effect of Bevacizumab Added to Carboplatin and Paclitaxel Chemotherapy on Hazard Ratios for Overall Survival for Adults age less than 65 years with Stage IIIB/IV, Non-squamous NSCLC
|Models |Hazard Ratio (95% CI) |
| |Bevacizumab |Bevacizumab |
| |Carboplatin-Paclitaxel- vs |Carboplatin-Paclitaxel- vs |
| |Carboplatin-Paclitaxel |Carboplatin-Paclitaxel |
| |2005-2010 |2002-2004 |
| |Age < 65 Years |Age < 65 Years |
|Unadjusted modela |0.81 (0.65-1.02) |0.64 (0.50-0.81) |
|Multivariable-adjusted modela,b |0.78 (0.62-1.00) |0.62 (0.48-0.80) |
|Propensity score-adjusted modela,c |0.79 (0.63-1.01) |0.64 (0.50-0.83) |
|Weighting (stabilized IPW) a, d |0.81 (0.57-1.17) |0.62 (0.47-0.81) |
|Matching 1:1e |0.88 (0.61-1.29) |0.53 (0.39-0.72) |
|Multivariable-adjusted Subgroup analyses |0.73 (0.57-0.95) |0.55 (0.42-0.73) |
|Stage IV f,b | | |
| Estimated comorbidity score of 0 g,b |0.84 (0.63-1.12) |0.71 (0.52-0.96) |
| Females Only h,b |0.77 (0.55-1.09) |0.62 (0.43-0.90) |
a Sample sizes: BCP vs CP 2005-2010 = 126 and 444, BCP vs CP 2002-2004 = 126 and 254
b The model was adjusted for age at diagnosis, sex, race/ethnicity, health plan, tumor grading, census tract education, modified Charlson comorbidities, and AJCC stage.
c The propensity of receiving BCP was estimated using a multivariable logistic regression model that included age at diagnosis, sex, race/ethnicity, health plan, tumor grading, census tract education, modified Charlson comorbidities, and AJCC stage. The propensity score was then added as a predictor in the survival model.
d The propensity score was used to create stabilized weights
e Sample sizes: BCP vs CP 2005-2010 = 123 and 123, BCP vs CP 2002-2004= 118 and 118, BCP and CP patients were matched based on their propensity score.
f Sample sizes: BCP vs CP 2005-2010 = 109 and 378, BCP vs CP 2002-2004= 109 and 199
g Sample sizes: BCP vs CP 2005-2010 = 88 and 295, BCP vs CP 2002-2004= 88 and 192
h Sample sizes: BCP vs CP 2005-2010 = 68 and 239, BCP vs CP 2002-2004 = 58 and 131
Table 2. Effect of Bevacizumab Added to Carboplatin and Paclitaxel Chemotherapy on Hazard Ratios for Overall Survival for Adults age greater than or equal to 65 years with Stage IIIB/IV, Non-squamous NSCLC
|Models |Hazard Ratio (95% CI) |
| |Bevacizumab |Bevacizumab |
| |Carboplatin-Paclitaxel- vs |Carboplatin-Paclitaxel- vs |
| |Carboplatin-Paclitaxel |Carboplatin-Paclitaxel |
| |2005-2010 |2002-2004 |
| |Age > 65 Years |Age > 65 Years |
|Unadjusted modela |0.76 (0.57-1.01) |0.61 (0.46-0.83) |
|Multivariable-adjusted modela,b |0.74 (0.54-1.00) |0.64 (0.46-0.88) |
|Propensity score-adjusted modela,c |0.79 (0.59-1.07) |0.66 (0.48-0.90) |
|Weighting (stabilized IPTW) a, d |0.75 (0.40-1.41) |0.59 (0.37-0.92) |
|Matching 1:1e |0.57 (0.29-1.12) |0.63 (0.38-1.02) |
|Subgroup analyses |0.72 (0.51-.1.01) |0.71 (0.50-1.02) |
|Stage IV f, b | | |
| Estimated comorbidity score of 0 g, b |0.63 (0.40-0.99) |0.64 (0.41-1.02) |
| Females Only h,b |0.72 (0.45-1.15) |0.57 (0.34-0.94) |
a Sample sizes: BCP vs CP 2005-2010 = 72 and 467, BCP vs CP 2002-2004= 72 and 242
b The model was adjusted for age at diagnosis, sex, race/ethnicity, health plan, tumor grading, census tract education, modified Charlson comorbidities, and AJCC stage.
c The propensity of receiving BCP was estimated using a multivariable logistic regression model that included age at diagnosis, sex, race/ethnicity, healthplan, tumor grading, census tract education, modified Charlson comorbidities, and AJCC stage. The propensity score was then added as a predictor in the survival model.
d The propensity score was used to create stabilized weights
e Sample sizes: BCP vs CP 2005-2010 = 69 and 69, BCP vs CP 2002-2004= 67 and 67, BCP and CP patients were matched based on their propensity score.
f Sample sizes: BCP vs CP 2005-2010 = 59 and 344, BCP vs CP 2002-2004= 59 and 162
g Sample sizes: BCP vs CP 2005-2010 = 33 and 210, BCP vs CP 2002-2004= 33 and 137
h Sample sizes: BCP vs CP 2005-2010 = 34 and 224, BCP vs CP 2002-2004= 34 and 120
................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Related download
- lippincott williams wilkins
- effectiveness of right heart catheterization in
- welcome to d scholarship pitt d scholarship pitt
- total direct and indirect effects
- 1 scottish government
- table 3 cambridge university press
- model selection in r donald bren school of information
- modeling observational data duke university
Related searches
- andy williams a time for us
- sherwin williams color of the year
- sherwin williams best neutrals 2019
- top sherwin williams neutral colors
- best sherwin williams cream colors
- best sherwin williams warm whites
- sherwin williams popular neutral colors
- sherwin williams paint names list
- top 10 sherwin williams colors
- sherwin williams most popular colors
- sherwin williams white paints
- most popular sherwin williams colors 2019